Novartis Cuts Patent From Suit Over Hemophilia Drugs
A unit of Swiss drugmaker Novartis AG has agreed to drop one of three patents asserted against Wyeth in an infringement suit over hemophilia treatments ReFacto and Xyntha....To view the full article, register now.
Already a subscriber? Click here to view full article